PT-141 dosage reference: typical range 0.5 – 2 mg, As needed (1–2 hours before), cycle As-needed only; max 8 doses per month per FDA guidelines. Titration…
FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder. Works in the brain to enhance sexual desire rather than just mechanical function.
Published protocol literature for PT-141 describes a typical range of 0.5 – 2 mg, dosed as needed (1–2 hours before), over a cycle of As-needed only; max 8 doses per month per FDA guidelines. Reported half-life: ~2 hours.
| Parameter | Reported value |
|---|---|
| Typical dose range | 0.5 – 2 mg |
| Frequency | As needed (1–2 hours before) |
| Cycle length | As-needed only; max 8 doses per month per FDA guidelines |
| Half-life | ~2 hours |
| Route | Subcutaneous injection (most published protocols) |
| Diluent | Bacteriostatic water |
| Commonly stacked with | Generally used alone; may combine with ED meds under medical supervision |
Protocols are usually titrated rather than started at the top of the range. The tiers below reflect how PT-141 dosing is commonly stepped in the published protocol literature.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 0.5–1 mg | As needed (1–2 hours before) | Assess response; expect flushing |
| Intermediate | 1–1.5 mg | As needed | Reliable arousal enhancement |
| Advanced | 1.5–2 mg | As needed (max 1×/24hr) | Maximum effect; manage nausea |
Concentration in mcg/mL equals vial milligrams multiplied by 1000, divided by the millilitres of bacteriostatic water added. Volume per dose in mL equals the target dose in mcg divided by that concentration. On a U-100 insulin syringe, multiply the volume in mL by 100 to read the units.
| Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|
| 2 mg vial | 1 mL bacteriostatic water | 2,000 mcg/mL |
| 5 mg vial | 2 mL bacteriostatic water | 2,500 mcg/mL |
| 10 mg vial | 2 mL bacteriostatic water | 5,000 mcg/mL |
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
Dose ranges on this page summarise published research and practitioner protocol literature for PT-141. They are a reference, not medical direction. All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Published protocol literature for PT-141 generally describes 0.5 – 2 mg, administered as needed (1–2 hours before). Individual protocols vary and should be set by a licensed practitioner.
As needed (1–2 hours before). Frequency is driven by half-life — PT-141 has a reported half-life of ~2 hours, so shorter-acting compounds are dosed more often.
Typical cycle length reported is As-needed only; max 8 doses per month per FDA guidelines. Cycling exists to limit receptor desensitisation and to create assessment windows, not as a fixed rule.
2mg → 1ml bacteriostatic water; 5mg → 2ml bacteriostatic water; 10mg → 2ml bacteriostatic water. Concentration in mcg/mL equals vial milligrams times 1000 divided by millilitres of bacteriostatic water.
PDE5 inhibitors (sildenafil, tadalafil) work on the vascular response. PT-141 acts upstream in the central nervous system on melanocortin receptors.